Theranostics = Diagnostics + Therapy
Theranostics combines diagnostic imagery to visualize tumors with the therapy to treat them, promoting patient-centered care and offering more personalized treatment. Custom Theranostic treatment plans can be devised that are unique to each individual, ensuring that the most effective treatment is administered at the right time.
Peptide Receptor Radionuclide Therapy (PRRT)
Theranostics uses Peptide Receptor Radionuclide Therapy (PRRT) which is targeted radiation to kill cancer cells from within.
The diagnostic component determines and defines the type and extent of the disease which allows decisions to be made on the timing, quantity, type of drugs, and choice of treatment options. The therapy component focuses on individualizing treatment by targeting therapy to an individual’s specific disease and administering the therapeutic agent to targeted sites of the disease which allows for higher doses administered safely to the site without significant exposure to normal tissue.
Adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that test positive for somatostatin receptors.
How PRRT Works
The diagnostic component of theranostics determines and defines the type and extent of disease.
This information allows decisions to be made on timing, quantity, type of drugs, and choice of treatment options, as well as helping to evaluate a patient’s response to treatment.
The development of the companion therapeutic component focuses on individualizing treatment by targeting therapy to the individual’s specific disease. Because the therapeutic agent is specifically targeted to sites of disease (with significantly reduced drug exposure to normal tissue), higher doses of the therapeutic agent may be safely administered.
UCBC is the only cancer center in northeast Georgia to offer theranostics treatment.
Current Available Treatments
LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.